N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1283-1288

  Rosato, Edoardo ^a   Cianci, Rosario ^a   Barbano, Biagio ^a   Menghi, Ginevra ^a   Gigante, Antonietta ^a   Rossi, Carmelina ^a   Zardi, Enrico M ^b   Amoroso, Antonio ^a   Pisarri, Simonetta ^a   Salsano, Felice ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME   (Italy)

Author keywords

Color Doppler sonography; N acetylcysteine; Renal blood flow; Resistance index; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; CARBON MONOXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; FEMALE; HUMAN; KIDNEY BLOOD FLOW; LUNG DIFFUSION CAPACITY; MALE; RENAL ARTERY; SYSTEMIC SCLEROSIS;

ACETYLCYSTEINE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; SCLERODERMA, SYSTEMIC; VASCULAR RESISTANCE;

EID: 70249136484     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.128     Document Type: Article

References (37)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
2. Belch JJF. The clinical assessment of scleroderma spectrum disorders. Br J Rheumatol 1993; 32: 353-356.
3. Denton CP. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology 2008; 47 Suppl 5: 54-56.
4. Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K, et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology (Oxford) 2001; 40: 406-409.
5. Scorza R, Rivolta R, Mascagni B, Berruti V, Bazzi S, Castagnone D, et al. Effect of iloprost infusion in the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997; 24: 1944-1948.
6. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-1901.
7. Merla A, Romani GL, Di Luzio S, Di Donato L, Farina G, Proietti M, et al. Raynaud's phenomenon: Infrared functional imaging applied to diagnosis and drug effects. Int J Immunopathol Pharmacol 2002; 15: 41-52.
8. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study. J Rheumatol 2001; 28: 2257-2262.
9. Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol 2005; 18: 761-770.
10. Sochman J, Peregrin JH. Total recovery of left ventricular function after acute myocardial infarction: comprehensive therapy with streptokinase, N-acetylcysteine and percutaneous transluminal coronary angioplasty. Int J Cardiol 1992; 35: 116-118.
11. Sochman J, Vrbska J, Musilova B, Rocek M. Infarct size limitation: Acute N-acetylcysteine defense (ISLAND) trial. Start of the study. Int J Cardiol 1995; 49: 181-182.
12. Jones DP. Redox potential of GSH/GSSG couple: Assay and biological significance. Methods Enzymol 2002; 348: 93-112.
13. Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens 2006, 24: 2263-2270.
14. Sahin G, Yalcin AU, Akcar N. Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients. Blood Purif 2007; 25: 309-315.
15. Fishbane S, Durham JH, Marzo K, Rudnick M. N-Acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004; 15: 251-260.
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Dignostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
17. Clements P, Lachenbruch P, Seibold J, Zee B, Steen VD, Brennan P, et al. Inter- and intraobserver variability of the total thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
18. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003; 62: 904-905.
19. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activ ity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-598. (Pubitemid 32493986)
20. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999; 26: 2159-2167.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
22. Kingdon EJ, Knight CJ, Dustan K, Irwin AG, Thomas M, Powis SH, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 2003; 42: 26-33.
23. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155-160.
24. Failli P, Palmieri L, D'Alfonso C, Black CM, Akesson A, Bacon PA, et al. Effect of N-acetyl-L-cysteine on peroxynitrite and superosside anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide 2002; 7: 277-282.
25. Platt JF. Duplex Doppler evaluation of native kidney dysfunction: Obstructive and nonobstructive disease. Am J Roentgenol 1992; 158: 1035-1042.
26. FitzGerald GA, Murray R, Price P, Catella F. The molecular, biochemical and human pharmacology of thromboxane A2 in renal disease. Adv Exp Med Biol 1989; 259: 325-360.
27. Pape L, Offner G, Ehrich JH. Renal arterial resistance index. N Engl J Med 2003; 349: 1573-1574.
28. Platt JK, Ruin JM, Ellis JH. Lupus nephritis: Predictive value of conventional and Doppler US and comparison with serologic and biopsy parameters. Radiology 1997; 203: 82-86.
29. Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr. Renal vascular histology and morphometry in systemic sclerosis. Arthritis Rheum 1988; 31: 393-400.
30. Rivolta R, Mascagni B, Berruti V, Quarto Di Palo F, Elli A, Scorza R, et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nepropathy. Arthritis Rheum 1996; 39: 1030-1034.
31. Aikimbaev KS, Canataro?lu A, Ozbek S, Usal A. Renal vascular resistance in progressive systemic sclerosis: Evaluation with duplex Doppler ultrasound. Angiology 2001; 52: 697-701.
32. Ogata C, Kamide K, Suzuki Y, Sasaki O, Kubota Y, Sato H, et al. Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade. Clin Nephrol 2005; 64: 352-357.
33. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 2003; 63: 634-641.
34. Chien, S, Li S, Shyy YJ. Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 1998; 31: 162-169.
35. Houston P, Dickson MC, Ludbrook V, White B, Schwachtgen JL, McVey JH, et al. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 1999; 19: 281-289.
36. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001; 281: F38-F47.
37. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005; 7: 1113-1123.